Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $812.00 Price Target at Sanford C. Bernstein

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lifted by research analysts at Sanford C. Bernstein from $756.00 to $812.00 in a report released on Monday, Benzinga reports. The firm presently has a “market perform” rating on the biopharmaceutical company’s stock. Sanford C. Bernstein‘s target price would indicate a potential downside of 15.46% from the stock’s current price.

A number of other analysts have also recently weighed in on the company. Piper Sandler increased their price target on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a research report on Monday, October 19th. The Goldman Sachs Group boosted their price objective on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Argus upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price objective for the company in a research note on Thursday, October 1st. Bank of America upped their price objective on Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday. Finally, HSBC increased their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $891.90.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded up $32.55 during trading on Monday, reaching $960.44. 975,692 shares of the company’s stock traded hands, compared to its average volume of 823,074. The stock has a market capitalization of $98.89 billion, a P/E ratio of 21.21, a price-to-earnings-growth ratio of 1.57 and a beta of 0.10. Regeneron Pharmaceuticals has a 12 month low of $591.52 and a 12 month high of $974.00. The company has a 50 day moving average of $793.30 and a 200-day moving average of $738.05. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. During the same quarter last year, the company posted $11.83 earnings per share. Regeneron Pharmaceuticals’s revenue was up 36.3% on a year-over-year basis. On average, equities analysts expect that Regeneron Pharmaceuticals will post 49.10 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director directly owned 603 shares of the company’s stock, valued at $512,550. The trade was a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the business’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the completion of the sale, the executive vice president owned 12,003 shares in the company, valued at approximately $10,291,252.17. This trade represents a 8.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 8,093 shares of company stock worth $6,506,845. Corporate insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Western Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $26,000. Armstrong Advisory Group Inc. grew its position in Regeneron Pharmaceuticals by 466.7% in the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 28 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $29,000. Trust Co. of Vermont acquired a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $29,000. Finally, Fiduciary Financial Advisors bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at $29,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts broadly raised their forecasts following the upbeat quarter. Guggenheim increased its target to $1,100 with a “buy” rating, JPMorgan raised its target to $1,050 and assigned an “overweight” rating, and Bank of America lifted its target to $1,030 while maintaining a “buy” rating. Other firms also raised targets, with some forecasts reportedly reaching as high as $1,175. Analysts Raise Their Forecasts on Regeneron Pharmaceuticals After Upbeat Q3 Results
• Positive Sentiment: The combination of 70% EPS growth, 36% revenue growth, continued Dupixent momentum, encouraging Libtayo data and an expanded BARDA Ebola-treatment supply agreement points to improving commercial execution and pipeline value. Regeneron Earnings Call Highlights Explosive Growth, Deep Pipeline
• Positive Sentiment: Recent earnings-driven buying pushed REGN to a new one-year high, signaling strong market momentum and improved sentiment around the company’s growth outlook. Regeneron Hits 52-Week High After Standout Q3
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3 to shareholders of record November 20. The annualized yield is approximately 0.4%, providing modest shareholder income.
• Negative Sentiment: Several updated targets remain below the current trading level: RBC set $913 with a “sector perform” rating, Wells Fargo set $925 with “equal weight,” and Baird set $875 with “neutral.” These calls suggest some analysts view the recent rally as having limited near-term upside.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.